175 related articles for article (PubMed ID: 20204403)
1. Serum Cyfra 21.1 and galectin-3 protein levels in relation to immunohistochemical cytokeratin 19 and galectin-3 expression in patients with thyroid tumors.
Išić T; Savin S; Cvejić D; Marečko I; Tatić S; Havelka M; Paunović I
J Cancer Res Clin Oncol; 2010 Dec; 136(12):1805-12. PubMed ID: 20204403
[TBL] [Abstract][Full Text] [Related]
2. [Expression of GADD153 in follicular tumors of thyroid and comparison with CK19, Galectin-3 and HBME-1].
Tang QS; Teng XD; Ding W; Zhou J; Yao HT; Ying LX; Xu LM
Zhonghua Bing Li Xue Za Zhi; 2011 Nov; 40(11):745-8. PubMed ID: 22336157
[TBL] [Abstract][Full Text] [Related]
3. Comparison of cytokeratin 19 expression in tumor tissue and serum CYFRA 21-1 levels in non-small cell lung cancer.
Kosacka M; Jankowska R
Pol Arch Med Wewn; 2009; 119(1-2):33-7. PubMed ID: 19341176
[TBL] [Abstract][Full Text] [Related]
4. Role of serum cytokeratin 19 fragment (Cyfra 21.1) as a prognostic biomarker in patients with differentiated thyroid cancer.
Giovanella L; Imperiali M; Trimboli P
Sci Rep; 2017 Aug; 7(1):7359. PubMed ID: 28779086
[TBL] [Abstract][Full Text] [Related]
5. Universal markers of thyroid malignancies: galectin-3, HBME-1, and cytokeratin-19.
Barut F; Onak Kandemir N; Bektas S; Bahadir B; Keser S; Ozdamar SO
Endocr Pathol; 2010 Jun; 21(2):80-9. PubMed ID: 20198455
[TBL] [Abstract][Full Text] [Related]
6. Circulating cytokeratin 19 fragments in patients with benign nodules and carcinomas of the thyroid gland.
Giovanella L; Ceriani L; Ghelfo A; Maffioli M
Int J Biol Markers; 2008; 23(1):54-7. PubMed ID: 18409152
[TBL] [Abstract][Full Text] [Related]
7. Expression of cytokeratin 19, HBME-1 and galectin-3 in neoplastic and nonneoplastic thyroid lesions.
Mataraci EA; Ozgüven BY; Kabukçuoglu F
Pol J Pathol; 2012 Mar; 63(1):58-64. PubMed ID: 22535608
[TBL] [Abstract][Full Text] [Related]
8. Cells of Benign and Borderline Thyroid Tumor Express Malignancy Markers.
Abrosimov AY; Dvinskikh NY; Sidorin AV
Bull Exp Biol Med; 2016 Mar; 160(5):698-701. PubMed ID: 27023100
[TBL] [Abstract][Full Text] [Related]
9. Serum biomarkers of papillary thyroid cancer.
Makki FM; Taylor SM; Shahnavaz A; Leslie A; Gallant J; Douglas S; Teh E; Trites J; Bullock M; Inglis K; Pinto DM; Hart RD
J Otolaryngol Head Neck Surg; 2013 Feb; 42(1):16. PubMed ID: 23663694
[TBL] [Abstract][Full Text] [Related]
10. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
11. [Usefulness of galectin-3 expression in the clinical behavior of differentiated thyroid carcinoma].
López Mondéjar P; Picó A; Seguí J; López Maciá A
Med Clin (Barc); 2008 Feb; 130(5):161-4. PubMed ID: 18341829
[TBL] [Abstract][Full Text] [Related]
12. [Expression of cytokeratin19, galectin-3 and HBME-1 in thyroid lesions and their differential diagnoses].
Teng XD; Wang LJ; Yao HT; Li J; Ding W; Yan LP
Zhonghua Bing Li Xue Za Zhi; 2004 Jun; 33(3):212-6. PubMed ID: 15256110
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma.
Zhu X; Sun T; Lu H; Zhou X; Lu Y; Cai X; Zhu X
J Clin Pathol; 2010 Sep; 63(9):786-9. PubMed ID: 20644217
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of cytokeratin-19, galectin-3, and Hector Battifora mesothelial-1 in the diagnosis of benign and malignant thyroid nodules.
Cui W; Sang W; Zheng S; Ma Y; Liu X; Zhang W
Clin Lab; 2012; 58(7-8):673-80. PubMed ID: 22997967
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules.
Park YJ; Kwak SH; Kim DC; Kim H; Choe G; Park DJ; Jang HC; Park SH; Cho BY; Park SY
J Korean Med Sci; 2007 Aug; 22(4):621-8. PubMed ID: 17728499
[TBL] [Abstract][Full Text] [Related]
16. Changes in galectin-7 and cytokeratin-19 expression during the progression of malignancy in thyroid tumors: diagnostic and biological implications.
Rorive S; Eddafali B; Fernandez S; Decaestecker C; André S; Kaltner H; Kuwabara I; Liu FT; Gabius HJ; Kiss R; Salmon I
Mod Pathol; 2002 Dec; 15(12):1294-301. PubMed ID: 12481010
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of serum C-reactive protein (CRP) and cytokeratin 19 fragments (Cyfra 21-1) but not carcinoembryonic antigen (CEA) in surgically treated patients with non-small cell lung cancer.
Szturmowicz M; Rudziński P; Kacprzak A; Langfort R; Bestry I; Broniarek-Samson B; Orłowski T
Pneumonol Alergol Pol; 2014; 82(5):422-9. PubMed ID: 25133810
[TBL] [Abstract][Full Text] [Related]
18. Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma.
Liu YY; Morreau H; Kievit J; Romijn JA; Carrasco N; Smit JW
Eur J Endocrinol; 2008 Mar; 158(3):375-84. PubMed ID: 18299472
[TBL] [Abstract][Full Text] [Related]
19. Correlation of Cyfra 21-1 levels in saliva and serum with CK19 mRNA expression in oral squamous cell carcinoma.
Malhotra R; Urs AB; Chakravarti A; Kumar S; Gupta VK; Mahajan B
Tumour Biol; 2016 Jul; 37(7):9263-71. PubMed ID: 26779624
[TBL] [Abstract][Full Text] [Related]
20. Serum cytokeratin 19 fragments: a dedifferentiation marker in advanced thyroid cancer.
Giovanella L; Treglia G; Verburg FA; Salvatori M; Ceriani L
Eur J Endocrinol; 2012 Dec; 167(6):793-7. PubMed ID: 22989467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
